Optimal dose suggested for dasatinib in ovarian cancer

November 19, 2012
Optimal dose suggested for dasatinib in ovarian cancer
A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer, according to research published in the Oct. 1 issue of Clinical Cancer Research.

(HealthDay)—A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer, according to research published in the Oct. 1 issue of Clinical Cancer Research.

As part of a phase I trial, Angeles Alvarez Secord, M.D., from the Duke University Medical Center in Durham, N.C., and colleagues treated a total of 20 patients with advanced and recurrent epithelial with escalating doses of dasatinib (100, 120, and 150 mg daily), combined with paclitaxel and carboplatin.

The researchers found that concurrent administration of dasatinib with paclitaxel did not significantly alter the effects of either dasatinib or paclitaxel. Grade 3 or 4 toxicities included myalgia, neutropenia, thrombocytopenia, and fatigue. Eight patients achieved complete or partial remission, 10 patients had stable disease, and two patients could not be evaluated. The median progression-free survival was 7.8 months and the median overall survival was 16.2 months. No biomarker could be identified to determine which patients would benefit from dasatinib.

"Due to the high incidence of myelosuppression with subsequent cycles, the recommended phase II dose of dasatinib is 150 mg daily in combination with paclitaxel and ," Secord and colleagues conclude. "The combination was safe with evidence of clinical activity."

The study was partially supported by a research grant from Bristol-Myers Squibb.

Explore further: Cetuximab, paclitaxel combo active in urothelial cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Cetuximab, paclitaxel combo active in urothelial cancer

August 29, 2012

(HealthDay)—The monoclonal antibody against epidermal growth factor receptor (EGFR), cetuximab, augments the antitumor activity of paclitaxel in patients with previously treated urothelial cancer, according to a study published ...

Recommended for you

Study: Colonoscopy after 75 may not be worth it

September 26, 2016

(HealthDay)—A colonoscopy can find and remove cancerous growths in the colon, but it may not provide much cancer prevention benefit after the age of 75, a new study suggests.

Research finds talc doesn't cause cancer; juries disagree

September 26, 2016

Two lawsuits ended in jury verdicts worth $127 million. Two others were tossed out by a judge who said there wasn't reliable evidence that the talc in Johnson & Johnson's iconic baby powder causes ovarian cancer. So who's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.